Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
about
Opportunity costs and local health service spending decisions: a qualitative study from WalesNovel Three-Day, Community-Based, Nonpharmacological Group Intervention for Chronic Musculoskeletal Pain (COPERS): A Randomised Clinical TrialUsing electronic health records to predict costs and outcomes in stable coronary artery diseaseDefining and Measuring the Affordability of New Medicines: A Systematic Review.Predicting future weight status from measurements made in early childhood: a novel longitudinal approach applied to Millennium Cohort Study dataThe use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review.Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.Local anaesthetic wound infiltration in addition to standard anaesthetic regimen in total hip and knee replacement: long-term cost-effectiveness analyses alongside the APEX randomised controlled trials.Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluationThe cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation.Assessing the validity of the ICECAP-A capability measure for adults with depression.Modelling the cost-effectiveness of public awareness campaigns for the early detection of non-small-cell lung cancer.Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the kneeCost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancerCurrent process and future path for health economic assessment of pharmaceuticals in France.Plans to accelerate innovation in health systems are less than IDEAL.Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.Expanded HTA, Legitimacy and Independence Comment on "Expanded HTA: Enhancing Fairness and Legitimacy"Comparison of Economic Evaluation Methods Across Low-income, Middle-income and High-income Countries: What are the Differences and Why?Caveat emptor NICE: biased use of cost-effectiveness is inefficient and inequitable.Preventing postnatal maternal mental health problems using a psychoeducational intervention: the cost-effectiveness of What Were We Thinking.Cost-effectiveness thresholds: pros and cons.Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.Comparative cost-effectiveness of focal and total salvage 125I brachytherapy for recurrent prostate cancer after primary radiotherapy.Healthy Life-Years Lost and Excess Bed-Days Due to 6 Patient Safety Incidents: Empirical Evidence From English Hospitals.Associations of participation in community assets with health-related quality of life and healthcare usage: a cross-sectional study of older people in the community.Should Countries Set an Explicit Health Benefits Package? The Case of the English National Health Service.Ethical Hurdles in the Prioritization of Oncology Care.Cost Considerations in the Evaluation and Treatment of Colorectal Cancer.Systematic Review of Hospital Based Cancer Registries (HBCRs): Necessary Tool to Improve Quality of Care in Cancer PatientsHow to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.Assessing and Communicating the Value of Biomedical Research: Results From a Pilot Study.Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.The effect of health care expenditure on patient outcomes: Evidence from English neonatal care.Economic evaluation of mental health interventions: an introduction to cost-utility analysis.Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.Sustainable Financing of Innovative Therapies: A Review of Approaches.Using Survival Analysis to Improve Estimates of Life Year Gains in Policy Evaluations.
P2860
Q27306722-F339890A-3701-4016-80A5-9AF0BCE4CF43Q28550243-48473A24-26AD-4D20-9810-47D4D35DB603Q28603610-D540C077-D92B-4434-9F32-2BE654789A75Q30234551-6CB6E9D8-43D8-4B88-A0B3-A3974A76427AQ31053932-08517901-99BA-401A-AD3C-CF863D7BEEC7Q33605471-10033AE7-22BD-469A-BD6F-CFAF4ACB5080Q33841955-C00C82DF-34DA-4EE6-9112-7497AA11043BQ35676055-2751584C-555A-4A91-B439-5BFAFC5DD252Q36213738-9A7955F3-9A6D-470E-A0A5-A5B720F36F15Q36259094-D8B0F187-3CD0-4D41-B4EA-AD640FD082E5Q36266693-09CB83F7-B456-49DD-B073-7C78329A20A0Q36286729-50699B61-EC14-4630-9F35-32A726A3E763Q36299326-433F9615-142F-49D1-A2B9-85F9D7FE8184Q36369497-351B59FB-CFD6-4A6B-8F8B-7F91737376B5Q36714654-EFD360B9-07D1-4AAA-AA7C-937DB68CE463Q37156367-A7796C8D-1A96-482A-A46F-BF3CED4ABB79Q37162297-8D56E10E-71A3-426D-94CF-45D7FF78259BQ37230755-2349DFA1-EB80-44D0-A18F-88FF78DE4F3DQ37295865-1261B38C-978F-4848-BA58-4F3205D1B484Q37357521-008C6A65-7B28-49BF-B3D4-BD20E9529B5AQ37454031-04DB28A5-6CF5-463D-A94C-E7E698316160Q37498173-C5B9F2CB-D7D8-4E05-9CE4-8503DBC735BEQ37507366-BFC96771-7873-40F8-A190-4C2D60F91993Q37540358-EB15D519-3AEC-4A39-8AB6-797A6EFC0916Q37590695-EE1CDD07-7B52-4403-9A0B-A9382E067CC0Q37606718-620F4E33-0325-466C-A91D-61F0D9ED8D99Q37639918-FFC6C2B8-74A8-4C5C-B51D-19FB0A4A3AD9Q37682715-3A7233A0-E957-42E0-A1AA-76BB9997065DQ37689561-8B840C1D-DAB3-4235-9C29-5BFD3A56691EQ38544945-7A8A47E5-F6DC-4F14-A940-735FC5B7EE37Q38607309-B44A4C44-4704-4EFC-B120-8EED6AB809DAQ38638180-7498309A-61A7-4519-B156-0CFA112C11CFQ38641699-242AAF89-E18E-4578-BA92-F76FB4F57486Q38714125-43D322CA-DADF-4B72-9C4A-6D586D57557CQ38758788-6234743C-6CFF-45CF-98CC-B4DA4C5E7E36Q38789998-79E72ABF-C1EC-45D1-9129-C83F17A4303DQ38807617-63C652AD-B13B-40C0-89F0-787C323C5314Q38814615-2DA457EF-45C6-4CE4-988E-7387DB6C4187Q38850678-F8686F46-330E-4B5D-AB19-E0431175B949Q38852135-697FCC67-D92D-4F77-A370-595078B3BEDE
P2860
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Methods for the estimation of ...... cost-effectiveness threshold.
@en
Methods for the estimation of ...... cost-effectiveness threshold.
@nl
type
label
Methods for the estimation of ...... cost-effectiveness threshold.
@en
Methods for the estimation of ...... cost-effectiveness threshold.
@nl
prefLabel
Methods for the estimation of ...... cost-effectiveness threshold.
@en
Methods for the estimation of ...... cost-effectiveness threshold.
@nl
P2093
P50
P356
P1476
Methods for the estimation of ...... cost-effectiveness threshold.
@en
P2093
Karl Claxton
Mark Sculpher
Nancy Devlin
Nigel Rice
Steve Martin
P304
1-503, v-vi
P356
10.3310/HTA19140
P577
2015-02-01T00:00:00Z